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Abstract
Background: All three nitric oxide synthase (NOS) isoforms are expressed in atherosclerotic plaques. NOS enzymes in
general catalyse NO production. However, under conditions of substrate and cofactor deficiency, the enzyme directly
catalyse superoxide formation. Considering this alternative chemistry, the effects of NOS on key events in spontaneous
hyperlipidemia driven atherosclerosis have not been investigated yet. Here, we evaluate how endothelial nitric oxide
synthase (eNOS) modulates leukocyte/endothelial- (L/E) and platelet/endothelial- (P/E) interactions in atherosclerosis and
the production of nitric oxide (NO) and superoxide by the enzyme.
Principal Findings: Intravital microscopy (IVM) of carotid arteries revealed significantly increased L/E-interactions in
apolipoproteinE/eNOS double knockout mice (apoE
2/2/eNOS
2/2), while P/E-interactions did not differ, compared to
apoE
2/2. eNOS deficiency increased macrophage infiltration in carotid arteries and vascular cell adhesion molecule-1
(VCAM-1) expression, both in endothelial and smooth muscle cells. Despite the expression of other NOS isoforms (inducible
NOS, iNOS and neuronal NOS, nNOS) in plaques, Electron Spin Resonance (ESR) measurements of NO showed significant
contribution of eNOS to total circulating and vascular wall NO production. Pharmacological inhibition and genetic deletion
of eNOS reduced vascular superoxide production, indicating uncoupling of the enzyme in apoE
2/2 vessels.
Conclusion: Overt plaque formation, increased vascular inflammation and L/E- interactions are associated with significant
reduction of superoxide production in apoE
2/2/eNOS
2/2 vessels. Therefore, lack of eNOS does not cause an automatic
increase in oxidative stress. Uncoupling of eNOS occurs in apoE
2/2 atherosclerosis but does not negate the enzyme’s strong
protective effects.
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Introduction
Atherosclerosis is a consequence of chronic inflammation of the
vessel wall [1]. One of the key events is the recruitment of
leukocytes and the adhesion of platelets to the endothelium
overlying the plaque [2,3]. Nitric oxide (NO), an important
physiological regulator of vascular homeostasis is implicated in the
pathophysiology of atherosclerosis [4]. In atherosclerotic plaques
all three NO-synthase (NOS) isoforms are expressed: the neuronal
(nNOS, NOSI), the inducible (iNOS, NOSII) and the endothelial
(eNOS, NOSIII)[5]. In contrast, in normal arteries eNOS is the
predominant NOS isoform [6]. While all NOS isoforms produce
NO by catalytic conversion of L-arginine to NO and L-citrulline,
the isoforms differ in catalytic activity, gene regulation and the
cellular compartment. Complicating the interpretation of the role
of NOS, all three isoforms can themselves produce superoxide
(termed ‘‘uncoupling’’), instead of NO, when substrate or cofactor
is limited [7,8,9]. eNOS and nNOS are constitutive enzymes
producing low concentrations of NO. We previously showed that
both, eNOS and nNOS significantly inhibit atherosclerosis in
apoE
2/2 mice [10,11]. In contrast to these protective effects,
iNOS produces high concentrations of NO, which serves
important roles in host defence against tumor cells and pathogens,
but also contributes to tissue damage in chronic inflammation and
increases apoE
2/2 atherosclerosis [12,13].
Pharmacological inhibition [14] and genetic deletion of eNOS
increases L/E- interactions in the microvasculature [15,16].
Further, NO decreases the expression of endothelial surface
adhesion molecules, including P-selectin and VCAM-1 [17,18]. In
apoE
2/2 atherosclerosis, L/E-interactions are increased, com-
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additionally modulates L/E-interactions in atherosclerosis has not
been directly assessed.
In addition, NO is a potential regulator of platelet activation,
platelet aggregation and P/E-interactions and multiple lines of
evidence suggest that platelets promote atherosclerosis [20,21,22].
In hypercholesterolemic animal models, platelet adhesion to the
endothelium occurs before plaques are visible [19,23]. Platelets
adhere to endothelial von Willebrand Factor (vWF) via glycopro-
teins (GP) and blockade of platelet GPIba profoundly reduces
lesion formation in apoE
2/2 mice [19]. Whether eNOS influences
P/E-interactions in atherosclerotic vessels on top of the changes
reported in apoE
2/2 compared to C57BL/6J wild type mice is
currently unknown.
Because of the changes in gene expression and the alternative
chemistry of NOS in atherosclerosis (NO vs. superoxide
production), the role of each NOS isoform on key events of
atherosclerosis can not be predicted. The anti-atherosclerotic and
anti-adhesive properties of NO depend on its bioavailability,
which is determined by the balance between its synthesis and
degradation. In situations of increased oxidative stress, low NO
bioavailability can result from NO’s reaction with superoxide,
giving rise to peroxynitrite formation [24], which in turn
contributes to oxidative stress [25]. Oxidation of the NOS cofactor
tetrahydrobiopterin (BH4) causes ‘‘uncoupling’’ of eNOS in vitro
and may be a major source of vascular superoxide production
promoting atherosclerosis [26,27,28].
The current study investigates the specific contribution of eNOS
to L/E- and P/E-interactions in atherosclerosis. The effects of
eNOS deletion on total vascular NO and superoxide productions
in atherosclerotic apoE
2/2 mice were studied with an aim to
determine which of these two radicals largely determine the key
events in atherosclerosis. Our results show that eNOS plays a
major role in protection against atherosclerosis despite the fact that
the enzyme is ‘‘uncoupled’’ and contributes to relevant superoxide
as well as nitric oxide production.
Methods
Ethics statement
All procedures performed were approved by the ethics
committee of University of Wu ¨rzburg (Approval No. 54-
2531.01-40/07).
Mice
Animals were backcrossed for 10 generations to the C57BL/6J
genetic background. eNOS
2/2, provided by Paul Huang [10],
and apoE
2/2 (Jackson Laboratories, Bar Harbor, ME, USA) were
crossed to generate double heterozygous mice. Offsprings were
crossed and progenies were genotyped for eNOS by southern
blotting and for apoE by polymerase chain reaction. apoE
2/2 and
apoE
2/2/eNOS
2/2 were weaned at 21 days and fed a western-
type diet for 18 weeks (42% of total calories from fat; 0.15%
cholesterol; Harlan Teklad, USA). For clear visualisation of L/E-
interactions through the vessel wall, IVM studies were performed
after 10 weeks of western-type diet, prior to macroscopic lesion
development in this vessel segment. Animals were maintained in
pathogen free facility with 12 hours light/dark cycle.
Assessment of L/E and P/E- interactions by IVM studies
L/E- and P/E-interactions were assessed in vivo by use of video
fluorescence microscopy [19]. Mice were anesthetized by
intraperitoneal injection of a solution of midazolame (5 mg/kg
body weight; Ratiopharm), medetomidine (0.5 mg/kg body
weight; Pfizer), and fentanyl (0.05 mg/kg body weight; CuraMed
Pharma GmbH). Due to easy accessibility, the carotid bifurcation
was chosen for IVM studies. The right common carotid artery was
carefully exposed, from 3 mm distal to 7 mm proximal to the
carotid bifurcation. Tissues were continuously superfused with a
thermostated bicarbonate-buffered saline solution, equilibrated
with 5% CO2 in nitrogen, to maintain a physiological pH.
Polyethylene catheters were implanted into the right jugular vein
for intravenous injections.
For platelet isolation, blood was collected from the retro-orbital
venous plexus of a donor mouse using heparin containing syringes.
Blood was centrifuged at 400 g for 5 minutes. The supernatant
was centrifuged at 250 g for 6 minutes to obtain platelet rich
plasma. Subsequently, the platelets were isolated by centrifugation
of the platelet rich plasma. The platelet pellet was re-suspended in
PBS (pH 7.4) and incubated for 2 minutes with the fluorochrome
carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular
Probes). Labelled platelets were centrifuged and pellets were re-
suspended in PBS and stored at room temperature until use. The
suspension was adjusted to a final concentration of 50610
6
platelets per 250 ml and infused intravenously into a recipient
mouse. As reported earlier, platelet preparation did not increase P-
selectin expression, indicating absence of platelet activation due to
preparation procedures [29]. Leukocytes were stained in vivo by
intravenous injection of 100 ml 0.02% rhodamine 6G (Molecular
Probes). The carotid artery was visualized using a Zeiss Axiotech
microscope (water immersion objective: 206,W2 0 6/0.5; Zeiss)
with a mercury lamp for epi-illumination. The experiments were
done as previously described [19]. L/E- and P/E-interactions
were determined at high magnification (500-fold) in a
200 mm6100 mm area. L/E- and P/E-interactions were studied
200 mm proximal to the carotid bifurcation, at a predilection site
for plaque development, which did not show macroscopic lesions
at the time of IVM.
All images were videotaped and evaluated off-line, using a
computer-assisted image analysis program (Cap Image 7.1; Dr. H.
Zeintl, Ingenieurbu ¨ro Dr. Zeintl, Heidelberg, Germany). The cells
that make an initial contact with the vessel wall followed by slow
surface translocation (with several further contacts) with a velocity
significantly lower than the centreline velocity were defined as
‘rolling cells’. Transiently adherent cells were defined as cells
crossing an imaginary perpendicular through the vessel at a
velocity significantly lower than the centreline velocity and were
quantified as cells per mm
2 endothelial surface. Cells that did not
move or detach from the endothelial surface within 20 seconds of
observation were defined as firmly adherent cells. All experiments
were performed by a blinded operator.
Evaluation of VCAM-1 RNA expression
Total RNA was isolated from the carotid arteries using a RNA
Miniprep Kit (Stratagene, CA, USA). cDNA was synthesised from
total RNA using the First Strand cDNA synthesis kit (Fermentas
GmbH, Germany). mRNA expression of VCAM-1 and CD14 was
quantified by real-time PCR (iCycler, Bio-Rad Laboratories,
USA). PCR amplification was performed for 40 cycles at primer
annealing of 60uC. VCAM-1 and CD14 expression was
normalized to the HPRT signal. VCAM-1 sense: 59-CTT GTG
TTG AGC TCT GTG GGT TT-39 and antisense: 59-CAA TCT
CCA GAT GGT CAA AGG GAT A -39. CD14 sense: 59- TAC
CGA CCA TGG AGC GTG TG-39 and antisense: 59-GCC GGT
TAC CTC GAG ATT TT-39. HPRT sense: 59- GTT GGA TAC
AGG CCA GAC TTT GT-39 and antisense: 59- CCA CAG GAC
TAG AAC ACC TGC-39. Fluorogenic probes for VCAM-1: 59-
6FAM- CTG TGC AGT TGA CAG TGA CAG GTC TCC C
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CCT CT –TMR; HPRT: 59-6FAM-CTC GTA TTT GCA GAT
TCA ACT TGC GC XT –PH were used. All primers and probes
were obtained from TIB Molbiol, Germany.
Histochemistry and immunohistochemistry
The area of the carotid arteries studied by IVM was stained
with Oil red O. Additionally, immunohistochemistry for VCAM-1
and macrophages were done. The carotid arteries isolated from
the anesthetized animals were embedded in Tissue-TekH (Sakura
Finetek, NL) and snap-frozen in liquid nitrogen. 5 mm sections
were cut and air dried. Sections were stained with Oil red O or
fixed in acetone for immunohistochemistry. Immunostaining for
macrophage was performed using a mouse macrophage/mono-
cyte monoclonal primary antibody (MOMA-2, Chemicon Int.)
and for VCAM-1 using an anti-mouse VCAM-1 antibody (R&D
systems). The macrophage and VCAM-1 stainings were visualised
using DAB (Vector laboratories).
Histomorphometry
Photomicrographs of the carotid artery were taken with a Leitz-
camera mounted on a light microscope (Carl-Zeiss, Jena,
Germany). Pictures were digitalized and transferred to a PC for
planimetry using Image Pro Plus (Version 4.1; Media Cybernet-
ics). All images were analysed at 400-fold magnification.
Macrophage positive areas and lipid rich areas in the common
carotid artery, in an area corresponding to the one used for IVM
studies, were measured. Results were expressed as % positively
stained plaque area.
Double immunofluorescence
To investigate the cellular compartment of VCAM-1 expres-
sion, cryosections of the aortic arch of apoE
2/2 and apoE
2/2/
eNOS
2/2 mice were fixed with acetone. Following blocking
procedures, cross reactivity of secondary antibodies with the
alternating primary antibodies was ruled out. Expression of
VCAM-1 protein in endothelial and smooth muscle cells was
examined by double immunofluorescence. Slides were incubated
with rat anti-VCAM-1 primary (BD Bioscience, 1:20) followed by
biotinylated rabbit anti-rat secondary antibody (Vector, 1:50) and
subsequently stained with streptavidin-texas red complex. After
washing, slides were incubated with the antibodies directed against
endothelial cells (rat anti-mouse CD 31, BD Bioscience, 1:100) or
vascular smooth muscle cells (a-actin, Sigma, 1:60). The latter
antibodies were directly labelled with fluoresceinisothiocyanate
(FITC, green). Finally, all sections were mounted with 49,6-
diamidino-2-phenylindole (DAPI) mounting media and examined
with a confocal microscope (Zeiss).
Hemodynamics of the carotid circulation
The animals were anesthetized and the common carotid artery
was visualized by duplex colour ultrasonography using an
ultrasound system with a 15 MHz transducer (NICE, Toshiba
Medical Systems, The Netherlands). The resistance index of the
common carotid artery was calculated as the difference between
the maximum systolic (Vsys) and the end-diastolic flow velocity
(Vdia) divided by Vsys.
Measurement of vascular NO production by electron
paramagnetic spintrapping
Detection of NO in the aorta was performed using colloid iron
(II) diethyldithiocarbamate (Fe(DETC)2) according to a method
which we adapted for detection of baseline NO production in
aortic rings of apoE
2/2 mice [30]. Briefly, animals were
anesthetized with pentobarbital (80 mg/kg i.p.) and the aorta was
perfused with 2 ml of Krebs-Hepes Buffer (KHB) through the left
ventricle. The aorta was removed rapidly and placed in a petridish
containing KHB. Perivascular fatty tissue was removed while the
aorta was maintained at 4uC in KHB using a cold plate (Noxygen
Science Transfer & Diagnostics, Denzlingen, Germany). The aorta
was cut into 2 mm rings and placed in one well of a 24 well plate
containing KHB. Subsequently, the aortic rings were incubated in
the colloidal Fe-(DETC)2 spin trap solution for 1 hour. The spin
trap was freshly prepared by mixing equal amounts of deoxygen-
ated 1.6 mM FeSO4 and 3.2 mM DETC solutions. For
pharmacological NOS inhibition samples were incubated with
the NOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME)
for 30 minutes at 37uC prior to the addition of spin trap. ESR
measurements were done using a bench top e-scan ESR
spectroscope (Bruker BioSpin GmbH, Germany). The instrumen-
tal settings were as follows: Centre field: 3308 G. Sweep width: 80
G. Microwave frequency: 9.495 GHz. Microwave power: 50 mW.
Modulation Amplitude: 4.6 G. Modulation frequency: 86 kHz.
Time constant: 81.92 ms. Conversion Time: 20.48 ms. Number of
scans: 100. The protein content of the samples was quantified
using a BCA protein assay kit (Pierce, IL, USA).
Measurement of NO bioavailability in the blood stream
Nitrosyl hemoglobin, a reaction product of deoxygenated
hemoglobin with NO is an in vivo marker for NO bioavailability
in the circulation [31] and can be detected as a characteristic
triplet peak by ESR spectroscopy. Blood samples were prepared
according to a published method [32]. Briefly, the venous blood
was drawn from the right ventricle. Following centrifugation at
2000 g (Eppendorf AG, Germany) the red cell cast was frozen in
syringes and transferred into a finger dewar containing liquid
nitrogen. The spectra were acquired using an X-band EMX
spectroscope (Bruker BioSpin GmbH, Germany) with the
following instrument settings: Centre field: 3340 G. Sweep width:
230 G. Microwave frequency: 9.452 GHz. Microwave power:
47.6 mW. Modulation Amplitude: 4.76 G. Modulation frequency:
86 kHz. Time constant: 40.96 ms. Conversion Time: 10.24 ms.
Number of scans: 24. The NO concentration was determined from
a calibration curve generated by incubating blood samples with
known concentrations of nitrite and sodium dithionite (Na2S2O4).
Measurement of intracellular superoxide production by
HPLC-detection of oxyethidium
Superoxide production was measured by incubating vessel rings
in KHB containing 50 mM dihydroethidium for 1 hour at 37uC
[33]. Aortic rings were then homogenized in ice cold methanol,
filtered and separated by reverse phase High Performance Liquid
Chromatography (HPLC) using a C-18 column (Nucleosil 250,
4.5 mm; Sigma-Aldrich) along with an AKTA HPLC system
(Amersham Biosciences, GE Healthcare). Oxyethidium, the
reaction product of superoxide and dihydroethidium was quan-
titated with a fluorescence detector (Jasco, UK) at an excitation
wavelength of 510 nm and emission wavelength of 595 nm. The
amount of oxyethidium formed was normalised to the protein
content of the samples.
Measurement of vascular superoxide production by ESR
Production of superoxide was measured in aortic rings
according to a previously published protocol [34] using the above
mentioned e-scan spectroscope. Superoxide production was
assessed by pre incubating aortic rings with PEG-SOD (100 U/
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tetramethylpyrrolidine (CMH) in KHB for 1 hour at 37uC. The
conversion of CMH to CM. radical in the PEG-SOD untreated
samples was used to determine the total production of reactive
oxygen species (ROS). The instrumental settings were as follows:
Centre field: 3388 G. Sweep width: 132 G. Microwave frequency:
9.497 GHz. Microwave power: 1.25 mW. Modulation Amplitude:
1.63 G. Modulation frequency: 86 kHz. Time constant: 40.96 ms.
Conversion Time: 10.24 ms. Number of scans: 50. The intensity
of the ESR signal was normalized to the sample’s protein content
using a BCA protein assay kit.
Western blot analysis
Aortic protein was isolated using RIPA buffer and western blots
were performed using a monoclonal rabbit anti-eNOS, anti-nNOS
(BD Biosciences) and a polyclonal anti-iNOS (Santa Cruz
Biotechnology, Inc.) antibodies. To confirm equal loading of
protein a goat anti-a-actin-antibody (Santa Cruz Biotechnology,
Inc.) was used. Blots were analysed densitometrically using Scan
Pack software (Biometra, Gottingen, Germany) and the density of
protein bands for iNOS and nNOS were normalised to the
corresponding a-actin bands of the same blots. Low temperature
SDS-PAGE followed by western blot was done as mentioned
previously for eNOS dimer/monomer protein detection [35].
Statistical analyses
All data were expressed as mean6SE. Two way ANOVA was
used for repeated measures, followed by Scheffe’s F-test (Stat View
4.51, Abacus Concepts, Inc., Berkley, CA, USA). Student’s t-test
was used for unpaired data. A probability value of p#0.05 was
considered significant.
Results
Genetic deletion of eNOS increases L/E-interactions in
apoE
2/2 mice
We used IVM to test whether eNOS derived NO affects L/E-
interactions and whether these changes occur prior to macroscopic
lesion formation. L/E-interactions were monitored in the common
carotid artery, at a predilection site for plaque development that
did not show macroscopic atherosclerotic lesions at the time of
study. The number of rolling leukocytes was significantly higher in
apoE
2/2/eNOS
2/2 (206624 cells/mm2, n=16), compared to
apoE
2/2 (125617 cells/mm2, n=23, p,0.01, Figure 1a). The
number of transiently adherent leukocytes was higher in apoE
2/2/
eNOS
2/2 (442650 cells/mm2, n=16), compared to apoE2/2
(155618 cells/mm2, n=23, p,0.0001, Figure 1b). Finally,
leukocyte firm adhesion was highly elevated in apoE
2/2/
eNOS
2/2 (94615 cells/mm2, n=16), compared to apoE
2/2
controls (2868 cells/mm2, n=23, p=0.0002, Figure 1c).
eNOS deficiency does not modulate platelet adhesion in
apoE
2/2 mice
We investigated P/E-interactions to determine if eNOS
influences platelet activation and adherence in a hyperlipidemia
driven model of spontaneous atherosclerosis. Our results show no
significant difference in the number of rolling platelets between
apoE
2/2 (53612 cells/mm2, n=19) and apoE
2/2/eNOS
2/2
(41610 cells/mm2, n=16, p=0.48). The amount of transiently
adherent platelets (apoE
2/2: 505657 cells/mm2, n=9 vs.
apoE
2/2/eNOS
2/2: 417665 cells/mm2, n=9, p=0.33) and
firmly adherent platelets (apoE
2/2:4 2 610 cells/mm2, n=19 vs.
apoE
2/2/eNOS
2/2:2 0 613 cells/mm2, n=16, p=0.2, figures
not shown) were similar.
eNOS deficiency increases the expression of VCAM-1
In order to determine if eNOS deletion increases VCAM-1
expression we performed real time PCR experiments using total
RNA samples of carotid arteries. Our results revealed that the
mRNA expression of VCAM-1 was significantly higher in apoE
2/2
/eNOS
2/2 animals, compared to apoE
2/2 controls (4.361.1,
n=9 vs. 1.060.45, n=20, p,0.002, Figure 2a). Additionally,
immunohistochemistry showed increased endothelial VCAM-1
expression in apoE
2/2/eNOS
2/2 animals vs. apoE
2/2
(Figure 2b). In order to check the cellular compartment of
VCAM-1 expression, we performed double immunofluorescence
in the aortic arch. We observed increased expression of VCAM-1
both in the endothelial (CD31 positive cells, Figure 2c) and medial
smooth muscle cells (a-actin positive cells, Figure 2d) of apoE
2/2/
eNOS
2/2 compared to apoE
2/2 samples.
NO from eNOS influences macrophage infiltration into
the vessel wall
To evaluate whether increased VCAM-1 expression in the
carotid artery results in increased mononuclear leukocyte
Figure 1. L/E-interactions analysed by intravital microscopy. The number of rolling, transiently adherent and firmly adherent leukocytes was
significantly increased in the common carotid artery of apoE
2/2/eNOS
2/2 (n=16), vs. apoE
2/2 controls (n=23), a) *p,0.01; b) ***p,0.0001; c)
**p,0.001).
doi:10.1371/journal.pone.0030193.g001
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real time PCR. apoE
2/2/eNOS
2/2 showed a striking increase in
CD14 expression, compared to apoE
2/2 controls (4.263.3,
n=12 vs. 1.060.43, n=17, p,0.00002, Figure 3a). This finding
was supported by an increase of the macrophage positive staining
areas in vessels of apoE
2/2/eNOS
2/2 (5.160.98% positively
stained plaque area, n=10), compared to apoE
2/2 (2.260.48%
positively stained plaque area, n=9, p=0.02, Figure 3b).
Planimetry of the Oil red O positive, lipid rich areas in the vessel
wall proximal to the carotid bifurcation showed no significant
difference between apoE
2/2 (8.164.0% positively stained plaque
area, n=9) and apoE
2/2/eNOS
2/2 animals (5.062.5% posi-
tively stained plaque area, n=7, p=0.56). The latter finding
documents similar amounts of fatty streaks in the area of carotid
artery chosen for IVM measurements.
Unaltered vascular resistance index in eNOS deficiency
Duplex ultrasonography of the common carotid artery revealed
that the resistance index in both, the apoE
2/2 (0.75860.015,
n=17) and apoE
2/2/eNOS
2/2 (0.75460.014, n=10, p=0.88,
Figure 4a and b) did not differ. These results show that at the time
of the study, genetic deletion of eNOS did not change the
hemodynamics of the carotid circulation.
eNOS is a significant source of vascular wall NO
production and circulating NO
Quantitation of baseline NO production in the vasculature is a
challenging task, due to the radical’s short half-life and very low
bio available concentrations of NO. We used ESR, a method of
highest sensitivity and specificity, in order to measure vascular NO
production and NO levels in blood. Spin trapping of NO with
colloidal Fe-(DETC)2 was used to measure baseline NO
production of the vessel wall [30]. In addition, the paramagnetic
properties of nitrosyl hemoglobin were utilised along with the ESR
technique to quantify the in vivo concentrations of NO in whole
blood [31]. Baseline vascular NO production was significantly
lower in apoE
2/2/eNOS
2/2 (2.660.7 nM/mg protein, n=15)
than in apoE
2/2 (7.360.6 nM/mg protein, n=14, p,0.0001,
Figure 5a and b). NO levels were significantly higher in apoE
2/2
(7.360.6 nM/mg protein, n=14) compared to C57BL/6J vessels
(4.160.7 nM/mg protein, n=12, p,0.01, Figure 5b). As expect-
ed, no ESR signal was detected in conventional eNOS
2/2 mice.
Interestingly, baseline NO production was significantly higher in
apoE
2/2/eNOS
2/2(2.660.7 nM/mg protein, n=15) compared
to eNOS
2/2 (0.060 nM/mg protein, n=8, p#0.01, Figure 5b)
vessels. Inhibition of NOS using NG-nitro-L-arginine methyl ester
Figure 2. eNOS deletion increases VCAM-1 expression. a) Real time PCR analysis showed four fold increased expression of VCAM-1 mRNA in
apoE
2/2/eNOS
2/2 (n=9) carotids, compared to apoE
2/2 (n=20, *p,0.01). b) Immunohistochemistry confirmed increased endothelial VCAM-1
expression in carotid arteries of apoE
2/2/eNOS
2/2, compared to apoE
2/2. Arrows indicate positive DAB staining (internal carotid artery, location of
IVM). c) Double immunofluorescence staining of VCAM-1 protein in atherosclerotic lesions. Sections of the aortic arch of apoE
2/2 and apoE
2/2/
eNOS
2/2 animals were incubated with anti-VCAM-1 antibody (red) and anti-CD31 antibody (endothelial cells, green). Arrows indicate localization of
VCAM-1 in endothelial cells in the overlay (yellow). Increased endothelial expression of VCAM-1 was observed in apoE
2/2/eNOS
2/2 compared to
apoE
2/2. d) Increased medial smooth muscle cell expression of VCAM-1 was observed in advanced plaques in the aortic arch in apoE
2/2/eNOS
2/2
compared to apoE
2/2, as shown in yellow (arrows) by the double immunofluorescence staining of VCAM-1 (red) and smooth muscle cells (green).
doi:10.1371/journal.pone.0030193.g002
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both in apoE
2/2 (0.060 nM/mg protein, n=11, vs. basal,
p,0.0001, Figure 5c) and apoE
2/2/eNOS
2/2 mice
(0.460.2 nM/mg protein, n=17 vs. basal, p,0.01, Figure 5c).
Additionally, nitrosyl hemoglobin levels in blood samples,
reflecting bioavailable NO in the circulation, were reduced in
apoE
2/2/eNOS
2/2 (18686100 nM, n=11), compared to
apoE
2/2 controls (34636491 nM, n=13, p,0.01, Figure 5d).
eNOS is uncoupled and contributes to vascular
production of superoxide in apoE
2/2 mice
The HPLC measurements revealed higher vascular superoxide
levels in apoE
2/2 compared to apoE
2/2/eNOS
2/2 (20.360.9
AU/mg protein, n=23, vs. 13.661.1 AU/mg protein, n=13,
p,0.0001, Figure 6a). Total superoxide formation in apoE
2/2
was significantly increased compared to C57BL/6J (20.360.9
AU/mg protein, n=23 vs. 16.361.1 AU/mg protein, n=14,
Figure 3. NO from eNOS influences macrophage infiltration in the vascular wall. a) Real time PCR analysis of CD14 showed significantly
increased expression of CD14 mRNA in apoE
2/2/eNOS
2/2 (n=12) carotids, compared to apoE
2/2 (n=17, *p,0.00002). b) Immunohistochemistry for
MOMA-2 showed elevated vascular macrophage infiltration in carotid arteries of apoE
2/2/eNOS
2/2 (n=10), compared to apoE
2/2 (n=9, *p,0.05).
doi:10.1371/journal.pone.0030193.g003
Figure 4. Unaltered vascular resistance index in eNOS deficiency. a) Representative picture of duplex ultrasonography in carotid arteries. b)
Equal resistance index of carotid arteries from apoE
2/2, n=17, vs. apoE
2/2/eNOS
2/2, n=10, p=0.88, by duplex ultrasonography. NS denotes non-
significance.
doi:10.1371/journal.pone.0030193.g004
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between C57BL/6J and eNOS
2/2 mice (16.361.1 AU/mgp r o t e i n ,
n=14 vs. 18.261.5 AU/mg protein, n=12, p.0.05, Figure 6a).
Interestingly, genetic deletion of eNOS in apoE
2/2 resulted in a
significant reduction of superoxide levels compared to genetic deletion
of eNOS in C57BL/6J mice (apoE
2/2/eNOS
2/2 vs. eNOS
2/2:
13.661.1 AU/mg protein, n=13 vs. 18.261.5 AU/mg protein, n=12,
p,0.05, Figure 6a), suggesting that eNOS contributes to superoxide
production only in atherogenic mice. In addition to these results from
our genetic model of chronic eNOS deficiency, acute pharmacological
inhibition of NOS by L-NAME resulted in a significant reduction of
superoxide in apoE
2/2 (14.260.9 AU/mg protein vs. basal, n=15,
p,0.0001, Figure 6b) but not in C57BL/6J (16.661.8 AU/mgp r o t e i n ,
n=17 vs. basal, p.0.05) and apoE
2/2/eNOS
2/2 mice (12.460.6
AU/mg protein, n=12 vs. basal, p.0.05), suggesting that NOS
uncoupling contributes to oxidative stress in apoE
2/2.M o r e o v e r ,L -
NIO, a specific eNOS inhibitor significantly decreased superoxide
production in apoE
2/2, supporting partial uncoupling of eNOS
(15.061.1 AU/mg protein, n=19 vs. 20.360.9 AU/mgp r o t e i n ,
n=23, p,0.001, Figure 6c). ESR measurements of total ROS
production, measured by the conversion of CMH to CM. showed a
significant increase in ROS levels in apoE
2/2 (17.961.7 nM/mg
protein, n=23) compared to C57BL/6J (7.360.8 nM/mgp r o t e i n ,
n=12, p,0.0001) and apoE
2/2/eNOS
2/2 mice (7.260.9 nM/mg
protein, n=15, p,0.0001, Figure 6d). Consistently, measurements of
SOD inhibitable superoxide levels using ESR showed significantly
increased superoxide production in apoE
2/2 (9.860.8 nM/mg
protein, n=23) compared to C57BL/6J (3.960.7 nM/mgp r o t e i n ,
n=12, p,0.0001, Figure 6e) and apoE
2/2/eNOS
2/2 mice
(4.260.9 nM/mg protein, n=15, p,0.0001, Figure 6e). The
uncoupling of eNOS was confirmed by a western blot for eNOS
dimer/monomer. The aortic lysates of C57BL/6J animals showed
increased eNOS protein dimers while apoE
2/2 animals showed high
levels of eNOS protein monomers.
Figure 5. eNOS is a significant source of vascular wall NO production and circulating NO. a) ESR spectrum of NO-Fe-(DETC)2 in aortas of
apoE
2/2 and apoE
2/2/eNOS
2/2. Bold lines indicate apoE
2/2, stripped lines apoE
2/2/eNOS
2/2 and patterned lines buffer/spin trap alone. Arrows
show the typical 3 peaks NO-Fe-(DETC)2 signal. b) Vascular NO production in C57BL/6J (n=12), eNOS
2/2 (n=8), apoE
2/2 (n=14) and apoE
2/2/
eNOS
2/2 (n=15), *p#0.01, **p,0.001, ***p,0.0001). c) Vascular NO production with NOS inhibition using L-NAME in apoE
2/2 (n=11) and apoE
2/2/
eNOS
2/2 mice (n=16), *p,0.01, ***p,0.0001. d) Nitrosyl hemoglobin concentration of blood samples from apoE
2/2/eNOS
2/2 (n=11) vs. apoE
2/2
controls (n=13, *p=0.01).
doi:10.1371/journal.pone.0030193.g005
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Genetic deletion of eNOS resulted in significant increase of
iNOS protein expression in the aorta of apoE
2/2 mice compared
to controls (1.14+0.27, n=10 vs. 0.43+0.16, n=10, p,0.05,
Figure 7). The expression levels of nNOS protein did not differ
significantly between apoE
2/2 and apoE
2/2/eNOS
2/2 mice
(0.90+0.23, n=10 vs. 0.85+0.14, n=11, p.0.05, Figure 7).
Discussion
Chronic eNOS deficiency significantly increases leukocyte
rolling, transient and firm adhesion in apoE
2/2/eNOS
2/2,
compared to apoE
2/2 controls. Increased L/E-interactions were
not due to differences in local plaque burden, as both genotypes
showed similar amounts of fatty streaks in carotid artery segments
used for IVM at an early time point. Duplex ultrasonography
studies documented similar hemodynamics in the carotid circula-
tion of both genotypes. Therefore, the increase in L/E-interactions
in apoE
2/2/eNOS
2/2 animals is not secondary to alterations of
flow dynamics.
To the best of our knowledge this is the first study investigating
the role of eNOS in L/E-interactions in spontaneous hyperlipi-
demia driven atherosclerosis. We show that lack of endogenous
NO production by eNOS accelerates L/E-interactions in apoE
atherosclerosis. Our data is in line with previous studies showing
that endogenous NO production inhibits L/E-interactions in the
microvasculature [15,16]. We previously reported that atheroscle-
rosis is accelerated in apoE
2/2/eNOS
2/2 and that this increase
in lesion formation is not secondary to increased blood pressure in
this genotype [10,36]. Therefore, increased atherosclerosis devel-
opment in apoE
2/2/eNOS
2/2 animals is likely due to local
changes like increased endothelial activation and L/E- interactions
reported here.
VCAM-1 expression is a hallmark of endothelial cell activation
[37]. In atherosclerosis, the interaction of macrophage very late
antigen-4 (VLA-4) and endothelial VCAM-1 mediates monocyte
firm adhesion. Upregulation of VCAM-1 expression following
treatment of human saphenous vein endothelial cells with the
NOS inhibitor L-NAME, suggests tonic suppression of adhesion
molecule expression by NO [18]. In contrast, our study of
microvascular endothelial cells from eNOS
2/2 mice showed that
eNOS deletion alone does not induce adhesion molecule
expression or increase L/E-interactions, suggesting that eNOS
serves a permissive role in endothelial activation [38]. The data
presented here indicates that eNOS deletion increases VCAM-1
expression not only in the endothelium, causing endothelial
activation and recruitment of leukocytes, but also in medial
smooth muscle cells.
Figure 6. eNOS is uncoupled and contributes to vascular production of superoxide in apoE
2/2 mice. a) HPLC measurements showed
lower levels of superoxide production in apoE
2/2/eNOS
2/2 (n=13) vs. apoE
2/2 (n=23). Superoxide levels were higher in apoE
2/2 (n=23) compared
to C57BL/6J (n=14). Interestingly, superoxide levels were significantly lower in apoE
2/2/eNOS
2/2 (n=13) compared to eNOS
2/2 (n=12). b) L-NAME
inhibited superoxide production in apoE
2/2 (n=15) but not in C57BL/6J (n=17) and apoE
2/2/eNOS
2/2 (n=12) aortas. c) Specific inhibition of eNOS
using L-NIO resulted in significant reduction of superoxide production in apoE
2/2 (n=19). d) Total ROS production using ESR showed a significant
increase in ROS levels in apoE
2/2 (n=23) compared to C57BL/6J (n=12) and apoE
2/2/eNOS
2/2 (n=15). e) Consistently, SOD inhibitable superoxide
production measured by ESR also showed significant increase in superoxide levels in apoE
2/2 (n=23) compared to C57BL/6J (n=12) and apoE
2/2/
eNOS
2/2 (n=15).
1p,0.05, *p,0.01, **p,0.001, ***p,0.0001, NS denotes non-significance. f) Uncoupling of eNOS in apoE
2/2 compared to C57BL/
6J aorta shown by western blot of eNOS protein dimer/monomer.
doi:10.1371/journal.pone.0030193.g006
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2/2 mice suggest that P/E-interactions are
an important trigger for plaque formation [19,39,40]. Since NO
was shown to inhibit platelet activation and aggregation in vitro,w e
studied the importance of eNOS derived NO in the modulation of
P/E-interactions in atherosclerosis. Our study shows no difference
in platelet rolling, transient, or firm adhesion to the endothelium in
apoE
2/2/eNOS
2/2 mice, compared to apoE
2/2 controls. This
suggests that the dramatically increased atherosclerosis in apoE
2/2
/eNOS
2/2, compared to apoE
2/2[10,41], is not caused by
increased platelet adhesion and subsequent events. Therefore,
although platelets accelerate plaque formation in apoE
2/2 mice,
they may not contribute to the increased plaque formation in
apoE
2/2/eNOS
2/2.
Spin trapping of NO by Fe-(DETC)2 using ESR, considered the
utmost specific and sensitive method for detection of NO in
biological systems, showed that eNOS contributes significantly to
total vascular NO production in atherosclerosis. We recently
reported that the significant increase in vascular NO production
observed in apoE
2/2 compared to C57BL/6J mice is due to
iNOS [42]. Interestingly, apoE
2/2/eNOS
2/2 mice had signifi-
cantly higher NO levels compared to eNOS
2/2 mice. This
increase in NO production is likely mediated by iNOS since aortic
iNOS protein expression was increased in apoE
2/2/eNOS
2/2
compared to apoE
2/2 (Figure 7). In contrast, we did not observe
changes in expression levels of nNOS in apoE
2/2 and apoE
2/2/
eNOS
2/2 (Figure 7). Consistent with the reduction of endothelial
NO production, the in vivo concentration of circulating nitrosyl
hemoglobin, reflecting bioavailable NO in the circulation, was
markedly reduced in apoE
2/2/eNOS
2/2 mice. Considering the
expression of all three NOS isoforms in atherosclerotic plaques,
our results are not easily predictable because of several reasons.
First, increased L/E-interactions, macrophage infiltration, in-
creased vascular iNOS expression and plaque area secondary to
eNOS deletion could have also resulted in increased cytotoxic NO
formation by iNOS. Secondly, the deletion of eNOS could have
changed the bioavailability of substrate and co-factor, thereby
influencing the chemistry of iNOS and nNOS. Our data suggest
that eNOS is an important source of vascular and circulating NO
in apoE
2/2 mice, despite all these possibilities. The residual NO
detectable by the characteristic triplet ESR peak in apoE
2/2/
eNOS
2/2 indicates residual NO production by iNOS and
possibly nNOS in the vessel wall.
Our assessment of vascular superoxide formation using two
independent techniques revealed a significant reduction of
superoxide production following genetic eNOS deletion (chronic)
in apoE
2/2. Inhibition of NOS isoforms using L-NAME resulted
in significant reduction of superoxide production in apoE
2/2 but
not in C57BL/6J and apoE
2/2/eNOS
2/2, suggesting that NOS
is uncoupled only in atherogenic apoE
2/2 mice. Additionally,
acute pharmacological inhibition of eNOS using L-NIO reduced
superoxide formation in apoE
2/2. The reduction of vascular
superoxide in apoE
2/2/eNOS
2/2 reflects the contribution of
endothelial, eNOS derived superoxide production. Since both,
significant NO and superoxide production by eNOS is detectable
in apoE
2/2 mice we conclude that eNOS is partially uncoupled
during atherosclerosis development in this model. In support of
this our eNOS western blots showed increased eNOS monomer,
an indirect measure of eNOS uncoupling in apoE
2/2 mice. As
shown in eNOS over-expressing apoE
2/2 mice, increased
superoxide generation by uncoupled eNOS may accelerate
atherosclerosis [43]. However, despite decreased vascular super-
oxide formation in our apoE
2/2/eNOS
2/2 model, these animals
develop increased atherosclerosis, suggesting that the atheropro-
tective effect of decreased superoxide production does not
outweigh the proatherogenic effects of NO deficiency. In other
words, we made the intriguing observation that the increased
eNOS derived superoxide formation does not override the damage
caused by a concomitant decrease of NO production following
eNOS deletion. Ample evidence implicates increased superoxide
production in atherosclerosis [44,45]. Our data is consistent with
Figure 7. Vascular expression of NOS isoforms. Significantly increased expression of iNOS protein in the aorta of apoE
2/2/eNOS
2/2 (n=10)
compared to apoE
2/2 mice (n=10). The protein levels of nNOS did not differ between apoE
2/2 (n=10) apoE
2/2/eNOS
2/2 (n=11). * p,0.05, NS
denotes non-significance.
doi:10.1371/journal.pone.0030193.g007
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in apoE
2/2 compared to C57BL/6J animals. Therefore, eNOS
uncouplingisa keysourceofsuperoxideproduction intheapoE
2/2
model.
The major findings of our study indicate that lack of eNOS
reduces vessel wall oxidative stress in atherosclerosis despite
accelerated plaque formation, increased vascular inflammation
and L/E-interactions in apoE
2/2/eNOS
2/2 vessels. P/E-inter-
actions do not differ between apoE
2/2 and apoE
2/2/eNOS
2/2,
indicating that lack of NO production does not increase platelet
interactions on top of the apoE
2/2 background. Uncoupling of
eNOS occurs in apoE
2/2 atherosclerosis but does not negate the
enzyme’s strong protective effects. Hence, eNOS derived NO can
still play a protective role in a system of high oxidative stress,
potentially associated with increased peroxynitrite formation.
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